Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) insider John A. Latham sold 10,000 shares of the company’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $31.32, for a total transaction of $313,200.00. Following the completion of the sale, the insider now owns 252,200 shares in the company, valued at approximately $7,898,904. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) traded up 1.25% during midday trading on Wednesday, reaching $31.47. 296,316 shares of the company’s stock were exchanged. The stock’s market capitalization is $1.58 billion. The firm has a 50-day moving average of $32.29 and a 200-day moving average of $28.37. Alder BioPharmaceuticals Inc. has a 12-month low of $15.82 and a 12-month high of $39.43.
Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its earnings results on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.04. The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $1.14 million. The company’s quarterly revenue was up 112900.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.46) earnings per share. Analysts anticipate that Alder BioPharmaceuticals Inc. will post ($3.33) EPS for the current fiscal year.
A number of research firms recently weighed in on ALDR. Zacks Investment Research upgraded shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $38.00 target price on the stock in a report on Tuesday, September 27th. Jefferies Group restated a “buy” rating and issued a $62.00 target price on shares of Alder BioPharmaceuticals in a report on Wednesday, September 28th. Brean Capital began coverage on shares of Alder BioPharmaceuticals in a report on Friday, September 30th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Alder BioPharmaceuticals in a report on Tuesday, September 13th. They issued an “overweight” rating and a $40.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, Alder BioPharmaceuticals currently has an average rating of “Buy” and an average price target of $45.00.
Several large investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its stake in shares of Alder BioPharmaceuticals by 110.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,844 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 2,016 shares during the last quarter. Macquarie Group Ltd. raised its stake in shares of Alder BioPharmaceuticals by 43.5% in the second quarter. Macquarie Group Ltd. now owns 100,450 shares of the biopharmaceutical company’s stock worth $2,508,000 after buying an additional 30,450 shares during the last quarter. Royal Bank of Canada bought a new stake in shares of Alder BioPharmaceuticals during the second quarter worth $4,253,000. Schwab Charles Investment Management Inc. raised its stake in shares of Alder BioPharmaceuticals by 76.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 158,058 shares of the biopharmaceutical company’s stock worth $3,947,000 after buying an additional 68,610 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Alder BioPharmaceuticals by 5.9% in the second quarter. American Century Companies Inc. now owns 77,244 shares of the biopharmaceutical company’s stock worth $1,929,000 after buying an additional 4,274 shares during the last quarter.
Alder BioPharmaceuticals Company Profile
Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.